menu
    • menu

    Company profile for Evopoint Biosciences

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 2017, Sinovent, relying on the concept of Sinovent’s dimensional guideline and evolution, has created a new generation of Best-in-Class products around mature targets and First-in-Class products with new targets in two dimensions. Innovate product layout, take into account the success rate of R&D and commercial value, and accelerate the development and marketing process of drugs. Sinovent is committed to creating...
    Founded in 2017, Sinovent, relying on the concept of Sinovent’s dimensional guideline and evolution, has created a new generation of Best-in-Class products around mature targets and First-in-Class products with new targets in two dimensions. Innovate product layout, take into account the success rate of R&D and commercial value, and accelerate the development and marketing process of drugs. Sinovent is committed to creating the best targeted therapy platform, antibiotic platform and PROTAC platform. At present, 6 varieties are in the clinical stage, of which XNW4107 and XNW3009 are about to enter phase III clinical trials.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Evopoint BiosciencesChina Flag
    Country
    Country
    China
    Address
    Address
    Building 22, Phase II, Bio-Industrial Park, No. 218, Sangtian Street, Suzhou I...
    Telephone
    Telephone
    +0512-89162086
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.evopointbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Astellas aims for CLDN18.2 gold with $1.34B licensing deal
    Astellas aims for CLDN18.2 gold with $1.34B licensing deal

    29 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/astellas-enters-exclusive-license-agreement-with-evopoint-biosciences-for-xnw27011--a-novel-clinical-stage-antibody-drug-conjugate-targeting-cldn18-2--302469022.html

    PR NEWSWIRE
    29 May 2025
    Share Share
    Evopoint Announces Trial Agreement with MSD for the Study of XNW5004
    Evopoint Announces Trial Agreement with MSD for the Study of XNW5004

    06 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230406005013/en

    BUSINESSWIRE
    06 Apr 2023
    Share Share
    AmMax Enters into an Agreement with Evopoint to License ADC
    AmMax Enters into an Agreement with Evopoint to License ADC

    09 Jan 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/01/09/2585142/0/en/AmMax-Bio-Enters-into-an-Exclusive-Option-Agreement-with-Evopoint-Biosciences-to-License-a-Next-Generation-Antibody-Drug-Conjugate-ADC-for-the-Treatment-of-Solid-Tumors.html

    GLOBENEWSWIRE
    09 Jan 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search